分组1 - Bolt Biotherapeutics reported a quarterly loss of $3.84 per share, better than the Zacks Consensus Estimate of a loss of $4.3, and improved from a loss of $7.6 per share a year ago, resulting in an earnings surprise of +10.70% [1] - The company achieved revenues of $2.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 150.00%, compared to zero revenues a year ago [2] - The stock has underperformed, losing about 24.5% since the beginning of the year, while the S&P 500 declined by only 1% [3] 分组2 - The earnings outlook for Bolt Biotherapeutics is uncertain, with current consensus EPS estimates of -$4.21 on $1.5 million in revenues for the coming quarter and -$12.51 on $3.5 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8] - The estimate revisions trend for Bolt Biotherapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Financial Performance - The company has incurred significant net losses of $33.4 million and $63.1 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $460.8 million as of December 31, 2025[117]. - The company has not generated any product revenue since its inception in 2015 and anticipates continuing to incur significant operating losses for the foreseeable future[117]. - The company expects its cash and cash equivalents of $31.8 million as of December 31, 2025, will not be sufficient to fund operations through the next twelve months, raising substantial doubt about its ability to continue as a going concern[121]. - The company has federal and state net operating loss carryforwards of $294.6 million and $351.1 million, respectively, as of December 31, 2025, with some carryforwards subject to expiration beginning in 2035[135]. Clinical Development and Regulatory Risks - The company has not completed any clinical trials or obtained regulatory approvals, which may delay its ability to generate product revenue[116]. - The company acknowledges that its expenses could increase significantly if required to perform additional studies or trials by regulatory authorities[118]. - The company may experience significant delays or an inability to successfully complete clinical trials, obtain regulatory approval, or commercialize product candidates, which would materially harm its business[140]. - The company may seek accelerated approval for some product candidates, but the FDA may require additional clinical trials before considering a Biologics License Application[150]. - Delays in clinical trials may occur due to various factors, including reaching consensus with regulatory authorities and patient enrollment challenges[154]. - The company is at risk of regulatory authorities withdrawing or suspending approvals of its products, which could harm its business prospects[164]. Competition and Market Challenges - The company competes with major pharmaceutical and biotechnology companies in developing immunotherapies for cancer, which may affect its market position[174]. - The company anticipates that its product candidates, if approved, will be priced at a significant premium over competitive generic products, potentially impacting market acceptance[175]. - Market acceptance of product candidates depends on various factors, including competition from other therapies and public perception of safety[190]. - The company faces significant competition in securing collaborations, with established companies having advantages in resources and capabilities[212]. Manufacturing and Supply Chain Risks - The company relies on third parties for the manufacture of its product candidates and does not own or operate any manufacturing facilities[128]. - The company relies on third-party manufacturers for clinical and commercial supplies, exposing it to risks related to production and regulatory compliance[201]. - Failure of third-party manufacturers to meet regulatory standards could lead to significant disruptions in supply and potential regulatory actions[202]. - Significant scale-up of manufacturing may require additional processes, technologies, and validation studies, which are costly and may not be successful[204]. Intellectual Property and Legal Risks - The company has two issued U.S. patents solely owned and four issued U.S. patents co-owned with Stanford, which are critical for competitive advantage[234]. - The patent position of biotechnology and pharmaceutical companies is uncertain, involving complex legal questions and potential litigation, which could harm competitive position and financial condition[237]. - The company is heavily dependent on licensed intellectual property, and losing rights to such licenses could significantly harm business operations and financial condition[242]. - The company may face disputes regarding the scope of rights granted under license agreements, which could narrow the perceived rights to intellectual property[244]. - The company may incur significant expenses and distractions from litigation related to intellectual property claims[275]. Regulatory Compliance and Healthcare Environment - The company is subject to various healthcare fraud and abuse laws, and non-compliance could lead to substantial penalties[219]. - Legislative changes, such as the ACA and the OBBBA, may increase the difficulty and cost of obtaining marketing approval and affect pricing strategies[214][215]. - The company is subject to stringent U.S. and foreign laws related to data privacy and security, which could lead to significant penalties if not complied with[222]. - Compliance with current good manufacturing practice (cGMP) and good clinical practice (GCP) is essential, and failure to comply may lead to unreliable data and delays in regulatory approval[208]. Workforce and Operational Challenges - Retaining key executives and qualified personnel is critical for the company's success in the competitive pharmaceutical industry[285]. - A restructuring and reduction-in-force was initiated in May 2024, with a new President and CEO appointed[286]. - The company faces intense competition for qualified personnel, which has led to unwanted employee attrition and may continue to impact its growth strategy[289]. - The company plans to expand its development and regulatory capabilities, which may lead to difficulties in managing growth and could disrupt operations[290]. Economic and Market Conditions - Macroeconomic uncertainties, including inflation and supply chain disruptions, could adversely affect the company's operations and clinical development timelines[282]. - The trading price of the company's common stock may be volatile, influenced by factors such as regulatory decisions and clinical trial results[301]. - Unstable market conditions, including inflation and geopolitical conflicts, may adversely affect the company's financial condition and share price[303]. - The company may experience a less active trading market for its common stock due to its reliance on exemptions from certain reporting requirements, potentially leading to increased price volatility[314].

Revenue - Collaboration revenue for Q4 2025 was $2.5 million, compared to $0 in Q4 2024, and total collaboration revenue for the full year 2025 was $7.7 million, consistent with 2024[12]. Expenses - Research and Development (R&D) expenses decreased to $5.0 million in Q4 2025 from $11.7 million in Q4 2024, and for the full year, R&D expenses were $28.5 million, down from $57.5 million in 2024[12]. - General and Administrative (G&A) expenses were $3.1 million for Q4 2025, down from $3.9 million in Q4 2024, and for the full year, G&A expenses were $13.8 million compared to $18.5 million in 2024[12]. - The company reported depreciation and amortization expenses of $1,291 in 2025, down from $1,781 in 2024, which is a reduction of about 27%[16]. - Non-cash lease expenses were $2,526 in 2025, slightly up from $2,297 in 2024, indicating a rise of about 10%[16]. Losses - Loss from operations for Q4 2025 was $7.1 million, a reduction from $16.9 million in Q4 2024, and the full-year loss from operations was $36.1 million compared to $73.0 million in 2024[12]. - The net loss for Q4 2025 was $6.6 million, compared to a net loss of $15.9 million in Q4 2024, and the full-year net loss was $33.4 million compared to $63.1 million in 2024[12]. - The net loss for 2025 was $33,376, a significant improvement compared to a net loss of $63,118 in 2024, reflecting a reduction of approximately 47%[16]. Cash Flow - Cash balance as of December 31, 2025, was $31.8 million, expected to fund key milestones into 2027[4]. - Net cash used in operating activities decreased to $39,850 in 2025 from $61,289 in 2024, indicating a 35% improvement in cash flow management[16]. - Cash, cash equivalents, and restricted cash at the end of the period increased to $13,441 in 2025 from $8,970 in 2024, representing a growth of approximately 50%[16]. - The total cash, cash equivalents, and restricted cash at the beginning of 2025 was $8,970, compared to $12,575 at the beginning of 2024, indicating a decrease of approximately 29%[16]. Investments - Net cash provided by investing activities was $44,302 in 2025, down from $57,576 in 2024, showing a decrease of about 23%[16]. - The company purchased marketable securities worth $29,016 in 2025, a reduction from $88,855 in 2024, indicating a strategic shift in investment approach[16]. - Proceeds from the issuance of common stock were $19 in 2025, a decline from $108 in 2024, reflecting a decrease of approximately 82%[16]. - The company experienced a gain on the sale of fixed assets amounting to $288 in 2025, compared to a gain of $70 in 2024, reflecting an increase of approximately 311%[16]. Clinical Development - Initial clinical data from the Phase 1 study of BDC-4182 is anticipated in Q3 2026, targeting gastric and gastroesophageal cancers[5]. - BDC-4182 demonstrated significant anti-tumor activity in preclinical models and has shown a strong immune response at initial dose levels[5]. - The company has two additional next-generation Boltbody™ ISAC programs targeting CEA and PD-L1 in preclinical development, currently on hold pending funding or partnerships[5]. Assets - Total assets decreased to $56.7 million as of December 31, 2025, from $99.6 million in 2024[14].

Core Insights - Bolt Biotherapeutics reported financial results for Q4 and full year 2025, highlighting collaboration revenue growth and ongoing clinical trials for its cancer immunotherapy candidates [1][4][10]. Financial Performance - Total collaboration revenue for Q4 2025 was $2.5 million, with full-year revenue at $7.7 million, compared to zero collaboration revenue in Q4 2024 [4][10]. - Research and development (R&D) expenses decreased to $5.0 million in Q4 2025 from $11.7 million in Q4 2024, and full-year R&D expenses were $28.5 million compared to $57.5 million in 2024 [10]. - General and administrative (G&A) expenses also saw a decline, totaling $3.1 million for Q4 2025, down from $3.9 million in Q4 2024, with full-year G&A expenses at $13.8 million compared to $18.5 million in 2024 [10]. - The company reported a loss from operations of $7.1 million for Q4 2025, significantly reduced from $16.9 million in Q4 2024, and a full-year loss of $36.1 million compared to $73.0 million in 2024 [10]. Clinical Development - BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), is currently in a Phase 1 dose-escalation trial targeting gastric and gastroesophageal cancers, with initial clinical data expected in Q3 2026 [2][6][8]. - The ISAC mechanism of BDC-4182 is distinct from traditional antibody-drug conjugates (ADCs) and T cell engagers, showing promising anti-tumor activity in preclinical models [2][6]. - The company has two additional ISAC programs targeting CEA and PD-L1 in preclinical development, which are currently on hold pending partnerships or funding [6][8]. Cash Position - As of December 31, 2025, the company had a cash balance of $31.8 million, which is expected to fund key milestones and operations into 2027 [5][6].

Core Insights - Bolt Biotherapeutics, Inc. reported a quarterly loss of $3.72 per share, which was better than the Zacks Consensus Estimate of a loss of $5.07, marking an earnings surprise of +26.63% [1] - The company generated revenues of $2.17 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 294.36% and showing an increase from $1.14 million in the same quarter last year [2] - The stock has underperformed, losing approximately 55.1% since the beginning of the year, while the S&P 500 has gained 16.4% [3] Financial Performance - Over the last four quarters, Bolt Biotherapeutics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$4.85 on revenues of $0.5 million, and for the current fiscal year, it is -$20.72 on revenues of $4.07 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bolt Biotherapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - For the three and nine months ended September 30, 2025, the net losses were $7.1 million and $26.7 million, respectively, compared to $15.2 million and $47.2 million for the same periods in 2024[108]. - The net loss for Q3 2025 was $7.1 million, an improvement from a net loss of $15.2 million in Q3 2024, while the nine-month net loss decreased to $26.7 million from $47.2 million[142]. - Interest income for Q3 2025 was $0.5 million, down from $1.3 million in Q3 2024, and for the nine months, it decreased to $2.1 million from $4.3 million[140]. - The company has incurred operating losses since inception and expects to continue incurring significant expenses and losses in the foreseeable future[108]. - The accumulated deficit as of September 30, 2025, was $454.1 million, indicating ongoing financial challenges[142]. Revenue and Collaborations - The company has not recorded any revenue from product sales, with all revenue derived from collaborations with Toray, Genmab, and Innovent[106]. - Collaboration revenue for Q3 2025 was $2.2 million, up from $1.1 million in Q3 2024, while nine-month revenue decreased to $5.2 million from $7.7 million in the same period[135]. - The company expects collaboration revenue to fluctuate based on the timing and outcome of development activities and payments from partners[121]. Expenses and Cost Management - Research and development expenses for Q3 2025 were $6.5 million, down from $13.8 million in Q3 2024, and for the nine months, expenses decreased to $23.5 million from $45.7 million[136]. - General and administrative expenses for Q3 2025 were $3.3 million, a decrease from $3.8 million in Q3 2024, and for the nine months, expenses decreased to $10.7 million from $14.5 million[138]. - The restructuring plan announced in May 2024 resulted in a workforce reduction of approximately 50 employees, or 50% of the workforce, with estimated charges of $3.6 million[104]. - A new restructuring plan was announced on October 1, 2025, to reduce operating expenses, including a further workforce reduction of approximately 20 employees, with estimated pre-tax charges of $1.5 million to $2.0 million[110]. Cash Flow and Funding - The company reported a net cash used in operating activities of $32.7 million for the nine months ended September 30, 2025, compared to $46.9 million for the same period in 2024[145]. - As of September 30, 2025, the company had cash and cash equivalents of $38.8 million, which is expected to fund operations into 2027[142]. - Net cash provided by investing activities was $43.2 million for the nine months ended September 30, 2025, compared to $45.3 million for the same period in 2024[146]. - The net cash provided by investing activities in 2025 included $59.5 million in maturities of marketable securities, offset by $17.2 million in purchases of marketable securities[146]. - Net cash provided by financing activities was $14,000 for the nine months ended September 30, 2025, compared to $0.1 million in 2024[147]. - Existing cash, cash equivalents, and marketable securities may be sufficient to fund operations into 2027, but there is substantial doubt about the company's ability to continue as a going concern[148]. - The company will need to raise additional capital to continue advancing its programs, with primary uses of cash including funding clinical trials and employee salaries[150]. - Future capital requirements will depend on various factors, including the ability to generate revenue from product sales and the success of collaborations[151]. - The company may finance cash needs through equity or debt financings, but there is a risk of dilution for existing stockholders[151]. Research and Development - The company is developing BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, with ongoing Phase 1 trials[102]. - BDC-3042, a dectin-2 agonist antibody, received IND clearance in July 2023, and the first patient was dosed in October 2023[103]. - The company has established a wholly-owned subsidiary in Australia to enhance its research and development capabilities in the region[107]. - The company anticipates continuing to incur research and development expenses as product candidates in later stages generally have higher costs[126]. - Future clinical development costs may vary significantly based on multiple factors, including trial costs and patient participation rates[130]. - Significant costs are associated with clinical trials and manufacturing product candidates, which are expected to grow as development progresses[150]. - The company faces uncertainties regarding the timing and costs of regulatory reviews and market acceptance of approved products[153]. Accounting Policies - There have been no material changes to critical accounting policies and estimates since the last annual report[156].

Financial Performance - Collaboration revenue for Q3 2025 was $2.2 million, up 92% from $1.1 million in Q3 2024[14] - Loss from operations for Q3 2025 was $7.7 million, significantly reduced from $16.4 million in Q3 2024, a decline of 53%[14] - Net loss for Q3 2025 was $7.1 million, compared to a net loss of $15.2 million in Q3 2024, a reduction of 53%[14] - Net loss for the nine months ended September 30, 2025, was $26,745 million, an improvement from a net loss of $47,182 million in the same period of 2024, representing a reduction of about 43.3%[18] Expenses - Research and Development (R&D) expenses decreased to $6.5 million in Q3 2025 from $13.8 million in Q3 2024, a reduction of 53%[14] - General and Administrative (G&A) expenses were $3.3 million in Q3 2025, down from $3.8 million in Q3 2024, a decrease of 13%[14] - Total operating expenses for Q3 2025 were $9.9 million, down from $17.6 million in Q3 2024, a decrease of 44%[14] - The company reported a stock-based compensation expense of $1,741 million for the nine months ended September 30, 2025, down from $6,225 million in the same period of 2024, a decrease of approximately 72%[18] Cash and Assets - Cash balance as of September 30, 2025, was $38.8 million, expected to fund operations into 2027[4] - Cash and cash equivalents increased from $7,205 million in December 2024 to $17,753 million in September 2025, a growth of approximately 146%[16] - Cash, cash equivalents, and restricted cash at the end of the period increased to $19,518 million from $11,139 million in the previous year, a rise of approximately 75.5%[18] - Total current assets decreased from $50,814 million in December 2024 to $35,606 million in September 2025, a decline of approximately 30%[16] - Total assets decreased from $99,632 million in December 2024 to $65,053 million in September 2025, a decline of about 34.7%[16] Liabilities and Equity - Total liabilities decreased from $42,434 million in December 2024 to $32,952 million in September 2025, a reduction of about 22.4%[16] - Total stockholders' equity decreased from $57,198 million in December 2024 to $32,101 million in September 2025, a decline of about 43.9%[16] Future Developments - Initial clinical data for BDC-4182 Phase 1 study is anticipated in Q3 2026, targeting gastric and gastroesophageal cancer[5] - BDC-4182 is a next-generation Boltbody™ ISAC candidate targeting claudin 18.2, with promising preclinical results indicating robust immune response[5] - The company is seeking a partner for further development of BDC-3042, a proprietary agonist antibody targeting dectin-2[8]

Core Insights - Bolt Biotherapeutics reported its financial results for Q3 2025, highlighting its focus on developing BDC-4182, a next-generation Boltbody™ ISAC for cancer treatment, with initial clinical data expected in Q3 2026 [1][2][4] Financial Performance - The company had a cash balance of $38.8 million as of September 30, 2025, which is anticipated to fund key milestones into 2027 [4][10] - Collaboration revenue for Q3 2025 was $2.2 million, an increase from $1.1 million in Q3 2024 [10][12] - Research and Development (R&D) expenses decreased to $6.5 million in Q3 2025 from $13.8 million in Q3 2024, primarily due to reduced salary and clinical expenses [10][12] - General and Administrative (G&A) expenses were $3.3 million in Q3 2025, down from $3.8 million in Q3 2024 [10][12] - The loss from operations was $7.7 million for Q3 2025, compared to $16.4 million for the same quarter in 2024 [10][12] Clinical Development - BDC-4182 is currently in a Phase 1 dose escalation study targeting gastric and gastroesophageal cancer, with initial data expected in Q3 2026 [2][5] - Preclinical data presented at the SITC indicated that BDC-4182 stimulates a strong immune response leading to complete tumor regression [5] - The company is also developing next-generation ISACs targeting CEA and PD-L1, with promising preclinical results [5] Collaborations and Partnerships - Ongoing collaborations with Genmab and Toray focus on developing additional next-generation ISAC programs for cancer treatment [5][10] - The company is seeking a partner for further development of BDC-3042, a proprietary agonist antibody targeting dectin-2 [10]

Core Insights - Bolt Biotherapeutics is a leader in the biotechnology sector, focusing on immuno-oncology agents to effectively target and destroy tumor cells [1] - The company has a stable financial outlook with a consensus price target of $7, and is expected to exceed earnings estimates in its upcoming report [2] Financial Performance - The company reported an EPS of -$4.46, surpassing expectations by $1.94, and revenue of $1.8 million, exceeding forecasts of $0.82 million [3] - Analysts forecast an EPS of -1.61 for the current year, despite a challenging return on equity of -69.46% [5] Product Development - Bolt is advancing its immunotherapy BDC-4182 through a Phase 1 dose-escalation study targeting gastric and gastroesophageal cancer, with initial results expected in the first half of 2026 [3] - The company is seeking a development partner for its dectin-2 agonist antibody, BDC-3042, which has shown promising outcomes in lung cancer patients [3] Institutional Interest - Institutional investors own 86.70% of Bolt's stock, with significant investments from Squarepoint Ops LLC and Millennium Management LLC [4] - The stock opened at $6.64, with a market capitalization of $254.58 million [4] Analyst Ratings - Analyst opinions vary, with Stifel Nicolaus adjusting their price target from $25.00 to $20.00 while maintaining a "hold" rating [5] - Lake Street Capital initiated coverage with a "buy" rating and a target price of $80.00 [5]

Core Viewpoint - Bolt Biotherapeutics, Inc. (BOLT) is anticipated to report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $5.07 per share, reflecting a year-over-year change of +36.6%, while revenues are projected to be $0.77 million, down 32.5% from the previous year [3]. - The consensus EPS estimate has been revised 0.83% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Bolt Biotherapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.33%, suggesting a bullish outlook on earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Bolt Biotherapeutics was expected to post a loss of $6.4 per share but actually reported a loss of -$4.46, achieving a surprise of +30.31% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Protagonist Therapeutics (PTGX) is expected to report a loss of $0.59 per share for the same quarter, with a year-over-year change of -9.3% and projected revenues of $10 million, up 113.7% from the previous year [18][19]. - Protagonist Therapeutics has a higher Most Accurate Estimate leading to an Earnings ESP of +29.92%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].